CA-170
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes[1][2].
Product Specifications
CAS Number
1673534-76-3
UNSPSC
12352005
Target
PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
Purity
99.39
Solubility
DMSO : 28.5 mg/mL (ultrasonic; warming)
Smiles
C[C@@H](O)[C@@H](C(O)=O)NC(N[C@H](C1=NC([C@@H](N)CO)=NO1)CC(N)=O)=O
Molecular Formula
C12H20N6O7
Molecular Weight
360.32
References & Citations
[1]Pottayil Govindan Nair Sasikumar, et al. 1,2,4-oxadiazole derivatives as immunomodulators. WO2015033299A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PAK6 (p21 Activated Kinase 6, p21-activated Kinase 6, p21(CDKN1A)-activated Kinase 6, PAK-6, Serine/threonine Protein Kinase PAK6, Serine/threonine Protein Kinase PAK-6) (Azide free) (HRP)
PAK6 (p21 Activated Kinase 6, p21-activated Kinase 6, p21(CDKN1A)-activated Kinase 6, PAK-6, Serine/threonine Protein Kinase PAK6, Serine/threonine Protein Kinase PAK-6) (Azide free) (HRP)